Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation

Lyden, PD; Pryor, KE; Minigh, J; Davis, TP; Griffin, JH; Levy, H; Zlokovic, BV

Lyden, PD (corresponding author), Univ Southern Calif, Zilkha Neurogenet Inst, Keck Sch Med, Dept Physiol & Neurosci, Los Angeles, CA 90007 USA.

FRONTIERS IN NEUROLOGY, 2021; 12 ():

Abstract

Ischemic stroke is the most widespread cause of disability and a leading cause of death in developed countries. To date, the most potent approved trea......

Full Text Link